HIV and HCV Intervention In Drug Treatment Settings - 1

NCT ID: NCT00102349

Last Updated: 2017-01-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

706 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-11-30

Study Completion Date

2006-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to test two strategies to reduce the risk of contracting Human Immunodeficiency Virus (HIV) or Hepatitis C Virus (HCV) by reducing risk behaviors in patients undergoing drug detoxification.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Behavior Therapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

PREVENTION

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Behavior Therapy

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Volunteers will be IV drug users already enrolled in drug detoxification treatment.
Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Oregon Health and Science University

OTHER

Sponsor Role collaborator

University of Colorado, Denver

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

University of Colorado at Denver

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Robert Booth, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

University of Colorado, Denver

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Denver Health & Hosp Authority

Denver, Colorado, United States

Site Status

Island Grove RTC

Greeley, Colorado, United States

Site Status

SSTAR (Stanley St. Treatment & Resources, Inc)

Fall River, Massachusetts, United States

Site Status

James Gilmore Jr. Treatment Center

Kalamazoo, Michigan, United States

Site Status

Willamette Family Treatment Services

Eugene, Oregon, United States

Site Status

SSTAR of Rhode Island - North Kingstown

North Kingstown, Rhode Island, United States

Site Status

Recovery Center King Co.-Kent Detox

Kent, Washington, United States

Site Status

Recovery Center King Co.-Seattle Detox

Seattle, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIDA-CTN-0017-1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

BEing Safe in Treatment
NCT03575585 COMPLETED PHASE2
Monitoring and Feedback in Substance Abuse Treatment
NCT01465490 COMPLETED PHASE1/PHASE2